Stock CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-07 pm EDT 		5-day change 1st Jan Change
236.3 USD +0.44% Intraday chart for Charles River Laboratories International, Inc. +3.19% -0.04%
Apr. 25 FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids CI
Apr. 24 Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
BU
Charles River Laboratories International : Proxy Supplement Filed April 24, 2024
PU
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
BU
Charles River Laboratories International : 2023 Corporate Citizenship Report
PU
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
BU
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
AQ
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
BU
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
BU
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
BU
Charles River to Perform Plasmid Production for Ship of Theseus
BU
Charles River to Perform Plasmid Production for Ship of Theseus
BU
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
BU
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
BU
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
BU
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
BU
Charles River Laboratories to Present at Barclays Global Healthcare Conference
BU
Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use
PR
Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
BU
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
BU
Charles River: Q4 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRL Stock
  4. News Charles River Laboratories International, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW